StockData
Olema Oncology, Inc. logo

Olema Oncology, Inc. (OLMA) stock

OLMANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/30
$7.06−0.16 (-2.22%)

Close on Nov 18, 2026Market cap $617.73MP/E –Yield –

Olema Oncology operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Olema Oncology's operating income for the twelve months ending Jun 30, 2026 was -$221.13M. For fiscal 2025 it was -$178.70M. The highest annual figure on record is -$4.32M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$178.70M–
FY2024Dec 31, 2024-$142.26M–
FY2023Dec 31, 2023-$104.96M–
FY2022Dec 31, 2022-$106.99M–
FY2021Dec 31, 2021-$71.49M–
FY2020Dec 31, 2020-$21.53M–
FY2019Dec 31, 2019-$4.32M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$67.18M–
Q1 FY2026Mar 31, 2026-$57.99M–
Q4 FY2025Dec 31, 2025-$50.08M–
Q3 FY2025Sep 30, 2025-$45.88M–
Q2 FY2025Jun 30, 2025-$47.86M–
Q1 FY2025Mar 31, 2025-$34.87M–
Q4 FY2024Dec 31, 2024-$36.77M–
Q3 FY2024Sep 30, 2024-$37.62M–
Q2 FY2024Jun 30, 2024-$33.53M–
Q1 FY2024Mar 31, 2024-$34.34M–
Q4 FY2023Dec 31, 2023-$30.42M–
Q3 FY2023Sep 30, 2023-$23.34M–
Q2 FY2023Jun 30, 2023-$21.60M–
Q1 FY2023Mar 31, 2023-$29.60M–
Q4 FY2022Dec 31, 2022-$27.22M–
Q3 FY2022Sep 30, 2022-$23.22M–
Q2 FY2022Jun 30, 2022-$33.29M–
Q1 FY2022Mar 31, 2022-$23.25M–
Q4 FY2021Dec 31, 2021-$21.76M–
Q3 FY2021Sep 30, 2021-$17.76M–
Q2 FY2021Jun 30, 2021-$16.52M–
Q1 FY2021Mar 31, 2021-$15.45M–
Q4 FY2020Dec 31, 2020-$10.13M–
Q3 FY2020Sep 30, 2020-$7.87M–
Q2 FY2020Jun 30, 2020-$2.49M–
Q1 FY2020Mar 31, 2020-$1.04M–

More Olema Oncology figures

See a number that looks wrong?